|
Q3 FY2026
As of Jul 31, 2026
|
Q2 FY2026
As of Apr 30, 2026
|
Q1 FY2026
As of Jan 31, 2026
|
Q4 FY2025
As of Oct 31, 2025
|
Q3 FY2025
As of Jul 31, 2025
|
Q2 FY2025
As of Apr 30, 2025
|
Q1 FY2025
As of Jan 31, 2025
|
Q4 FY2024
As of Oct 31, 2024
|
Q3 FY2024
As of Jul 31, 2024
|
Q2 FY2024
As of Apr 30, 2024
|
Q1 FY2024
As of Jan 31, 2024
|
Q4 FY2023
As of Oct 31, 2023
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Current assets: | ||||||||||||
| Cash and cash equivalents | ||||||||||||
| Marketable securities - short term | ||||||||||||
| Restricted investments | ||||||||||||
| Investment tax credits receivable | ||||||||||||
| Prepaid and other current assets | ||||||||||||
| Total current assets | ||||||||||||
| Marketable securities - long term | ||||||||||||
| Property and equipment, net | ||||||||||||
| Operating lease right of use asset | ||||||||||||
| Other assets | ||||||||||||
| Total assets | ||||||||||||
| Liabilities and shareholders' equity | ||||||||||||
| Current liabilities: | ||||||||||||
| Accounts payable | ||||||||||||
| Accrued expenses and other current liabilities | ||||||||||||
| Operating lease liabilities, current | ||||||||||||
| Current portion of note payable | ||||||||||||
| Total current liabilities | ||||||||||||
| Note payable, net of current portion | ||||||||||||
| Convertible debentures | ||||||||||||
| Operating lease liabilities, net of current portion | ||||||||||||
| Liabilities, Total | ||||||||||||
| Shareholder's equity: | ||||||||||||
| Common shares, no par value; unlimited shares authorized, 67,014,067 and 52,018,658 shares issued and outstanding as of July 31, 2026 and October 31, 2025, respectively. | ||||||||||||
| Additional paid-in capital | ||||||||||||
| Accumulated other comprehensive loss | ||||||||||||
| Accumulated deficit | ||||||||||||
| Total shareholder's equity | ||||||||||||
| Total liabilities and shareholders' equity |
Loading...
